Stelara was first approved in 2009 to treat psoriasis and psoriatic arthritis.
The anti-inflammatory drug, which posted $2.5 billion in sales for 2015, is one of New Brunswick, N.J.-based Johnson & Johnson’s biggest revenue generators.
The FDA based its approval on late-stage study results that show Stelara successfully treated patients with moderate-to-severe Crohn’s disease who did not respond to traditional medications.
More articles on supply chain:
Red Cross: Blood donations still needed to replenish supply
FDA approves handheld device to assess traumatic brain injury
Mylan underreported EpiPen profits by 60% at Congressional hearing
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
